Milestone Pharmaceuticals Inc. Logo

Milestone Pharmaceuticals Inc.

Developing a self-administered nasal spray for at-home treatment of acute cardiac events.

MIST | US

Overview

Corporate Details

ISIN(s):
USU6005B1045 (+1 more)
LEI:
549300P43IPGW3Q3Y026
Country:
United States of America
Address:
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, 07039 MONTREAL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for episodic cardiovascular conditions. The company's lead investigational product is etripamil, a proprietary, novel calcium channel blocker delivered as a self-administered nasal spray. This therapy is designed for the rapid termination of paroxysmal supraventricular tachycardia (PSVT) episodes in an at-home setting, addressing a significant unmet need for treatment outside of the emergency department. Milestone is also exploring etripamil's potential for other conditions, such as atrial fibrillation with rapid ventricular rate (AFib-RVR), to provide patients with control over acute cardiac events.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Milestone Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Milestone Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Milestone Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.